Loading...
XKRX102460
Market cap162mUSD
Dec 24, Last price  
12,920.00KRW
1D
0.94%
1Q
-11.23%
Jan 2017
-41.31%
IPO
21.99%
Name

Reyon Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:102460 chart
P/E
66.13
P/S
1.57
EPS
195.38
Div Yield, %
1.16%
Shrs. gr., 5y
1.64%
Rev. gr., 5y
4.20%
Revenues
151.07b
-1.93%
55,906,318,00072,932,904,00095,187,341,000120,827,191,000124,350,931,480114,334,848,060109,693,359,770112,112,066,710114,507,234,540121,847,219,920126,253,125,650122,990,417,380131,557,875,300130,034,153,190142,801,367,550154,038,839,260151,071,143,910
Net income
3.58b
-51.80%
6,086,421,0008,065,547,00016,287,993,00019,981,933,00019,779,374,32016,990,558,94011,292,961,39011,593,285,51011,337,932,74010,701,369,00012,886,901,0001,342,892,9105,941,669,8003,844,427,1405,537,251,5307,433,682,1603,583,373,120
CFO
8.65b
-0.96%
8,049,026,0005,985,742,0008,683,539,00018,191,445,00013,238,641,08022,070,046,340-51,792,71015,102,444,1709,663,900,5809,471,438,00016,763,965,00011,449,210,060-12,183,515,7504,599,406,54011,684,528,3508,729,174,3708,645,127,290
Dividend
Dec 27, 2023150 KRW/sh

Profile

REYON Pharmaceutical Co., Ltd. manufactures and sells finished medicines and APIs in South Korea and internationally. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
URL
https://reyonpharm.co.kr/en/main/main.do
IPO date
Jun 10, 2010
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
151,071,144
-1.93%
154,038,839
7.87%
142,801,368
9.82%
Cost of revenue
113,525,672
115,864,296
108,621,720
Unusual Expense (Income)
NOPBT
37,545,472
38,174,544
34,179,648
NOPBT Margin
24.85%
24.78%
23.94%
Operating Taxes
448,590
(539,767)
307,510
Tax Rate
1.19%
0.90%
NOPAT
37,096,882
38,714,310
33,872,137
Net income
3,583,373
-51.80%
7,433,682
34.25%
5,537,252
44.03%
Dividends
(2,737,914)
(4,563,189)
(3,464,053)
Dividend yield
0.90%
1.19%
0.55%
Proceeds from repurchase of equity
(3,830)
9,923,692
BB yield
0.00%
-1.58%
Debt
Debt current
102,265,540
24,754,331
24,410,890
Long-term debt
126,185,945
188,934,115
185,291,993
Deferred revenue
Other long-term liabilities
2,747,603
3,526,113
2,327,966
Net debt
182,994,506
171,428,067
118,405,432
Cash flow
Cash from operating activities
8,645,127
8,729,174
11,684,528
CAPEX
(28,869,949)
(63,133,217)
(116,996,723)
Cash from investing activities
(8,739,390)
(52,564,092)
(114,682,026)
Cash from financing activities
8,153,339
(6,767,466)
157,575,828
FCF
5,975,193
(26,173,810)
(74,035,084)
Balance
Cash
24,241,004
36,069,017
97,448,250
Long term investments
21,215,974
6,191,362
(6,150,800)
Excess cash
37,903,421
34,558,437
84,157,382
Stockholders' equity
214,748,543
221,739,437
219,063,872
Invested Capital
438,522,444
426,202,669
370,295,048
ROIC
8.58%
9.72%
10.67%
ROCE
7.88%
8.29%
7.52%
EV
Common stock shares outstanding
18,341
17,753
17,719
Price
16,540.00
-23.60%
21,650.00
-39.10%
35,550.00
60.86%
Market cap
303,359,991
-21.07%
384,347,189
-38.98%
629,921,257
67.38%
EV
486,354,497
556,025,256
748,576,690
EBITDA
42,327,706
42,708,054
38,845,351
EV/EBITDA
11.49
13.02
19.27
Interest
193,815
122,198
111,191
Interest/NOPBT
0.52%
0.32%
0.33%